Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pregabalin
Drug ID BADD_D01835
Description Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter.[A173995] It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions.[A187190] Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.[A187190][L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[L1006][L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.[A31161]
Indications and Usage Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.[L7066]
Marketing Status approved; investigational
ATC Code N02BF02
DrugBank ID DB00230
KEGG ID D02716
MeSH ID D000069583
PubChem ID 5486971
TTD Drug ID D00WUF
NDC Product Code 75834-303; 76282-569; 76282-572; 76420-118; 76420-122; 76420-221; 76420-248; 80425-0025; 80425-0129; 80425-0178; 0904-6991; 0904-7003; 42419-019; 53869-1014; 61294-9991; 64220-169; 65862-761; 65862-790; 0071-1019; 81999-0003; 82924-001; 25000-180; 27808-238; 31722-614; 43353-263; 43353-876; 43547-510; 43598-293; 46708-120; 50228-356; 0228-2859; 55154-8097; 55700-964; 59762-1346; 59762-1348; 59762-1354; 60505-3793; 60687-495; 62332-121; 63629-8208; 64980-410; 65862-759; 65862-760; 67877-466; 67877-469; 68788-7527; 69367-325; 69367-329; 69539-127; 70518-2745; 70518-2763; 71205-323; 71205-556; 71209-034; 71209-037; 71335-1792; 71610-318; 71610-319; 71610-350; 71610-351; 71610-352; 71610-358; 72189-019; 72205-018; 72606-006; 72658-0809; 72658-0849; 76282-568; 76420-095; 76420-117; 80425-0026; 80425-0027; 80425-0030; 80425-0170; 0904-7004; 0904-7005; 53869-1018; 53869-1019; 63415-0121; 66039-926; 0071-1020; 47335-687; 50228-351; 0228-2856; 0228-2860; 60505-3797; 60687-506; 60760-205; 60760-591; 63629-8239; 63629-8248; 64980-416; 68788-7522; 68788-8359; 69238-1315; 69539-012; 69539-016; 70518-3642; 70518-3647; 71335-1758; 71335-2000; 71610-071; 71610-316; 71610-333; 71610-361; 71610-618; 72162-1545; 72162-1548; 72189-115; 72606-007; 72606-008; 80425-0028; 50370-0013; 53869-1012; 53869-1016; 55111-882; 59285-002; 65862-758; 66174-0031; 0071-1012; 27808-235; 31722-610; 31722-615; 43598-297; 46708-124; 46708-125; 47335-692; 47335-693; 0228-2858; 55154-8098; 55700-774; 55700-891; 55700-955; 55700-956; 59762-1342; 59762-1364; 60219-1315; 60760-507; 62135-445; 62135-447; 62332-123; 62332-126; 63629-8196; 64980-413; 64980-415; 67877-464; 67877-467; 67877-468; 69097-957; 69097-961; 69238-1313; 69367-324; 69367-330; 69539-128; 70518-3646; 71205-396; 71205-873; 71209-038; 71335-1505; 71610-320; 71610-365; 71610-619; 71610-719; 72162-1546; 72162-2026; 72189-241; 72205-077; 55700-805; 59762-1360; 60219-1317; 60505-3799; 60760-485; 62135-446; 62332-124; 64980-411; 64980-414; 64980-417; 67877-462; 68788-7521; 68788-8383; 68788-8472; 69097-958; 69097-962; 69238-1311; 70518-2568; 70518-2571; 70518-2892; 70518-2980; 71205-304; 71335-1751; 71335-2012; 71335-9740; 71610-314; 71610-330; 72162-1541; 72162-2024; 72162-2028; 72189-033; 72205-016; 72205-017; 75834-297; 76420-247; 80425-0160; 80425-0307; 0904-7000; 0904-7001; 65862-763; 0071-1014; 0071-1015; 25000-185; 31722-612; 43353-840; 47335-689; 50228-357; 50228-463; 0228-2863; 59762-1344; 59762-1351; 60219-1311; 60505-3795; 60505-3798; 62332-122; 65862-765; 67877-457; 68788-8391; 69238-1316; 69539-015; 70518-2483; 70518-2525; 70518-2762; 71205-298; 71205-694; 71205-733; 71205-874; 71335-1459; 71335-1475; 71335-1762; 71335-9671; 71610-328; 72162-1544; 72189-269; 72189-328; 72658-0811; 76282-575; 76420-119; 76420-121; 76420-123; 80425-0147; 80425-0277; 80425-0308; 0904-6992; 15894-0016; 16812-003; 62331-057; 69218-0300; 27808-239; 27808-241; 31722-616; 31722-617; 43598-291; 43598-298; 47335-691; 50090-6503; 0228-2857; 55700-775; 55700-827; 55700-904; 60219-1310; 62332-120; 63304-047; 63629-8199; 67877-463; 68071-2330; 69238-1310; 69539-011; 69539-018; 69539-129; 71205-608; 71205-872; 71209-039; 71335-1744; 71335-2030; 71335-9699; 72162-1542; 72162-1543; 72189-021; 72189-164; 72205-013; 72205-015; 75834-302; 76420-099; 76420-102; 76420-124; 80425-0116; 0904-7002; 53869-2347; 65862-762; 0071-1013; 0071-1018; 0071-1026
UNII 55JG375S6M
Synonyms Pregabalin | (S)-3-(aminomethyl)-5-methylhexanoic acid | 3-isobutyl GABA | 3 isobutyl GABA | GABA, 3-isobutyl | 3-(aminomethyl)-5-methylhexanoic acid | (R-)-3-isobutyl GABA | (S+)-3-isobutyl GABA | Lyrica | CI 1008 | 1008, CI | CI-1008 | CI1008
Chemical Information
Molecular Formula C8H17NO2
CAS Registry Number 148553-50-8
SMILES CC(C)CC(CC(=O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Withdrawal syndrome08.06.02.012; 19.07.06.0230.031887%Not Available
Xerophthalmia14.12.03.002; 06.06.03.0080.000078%Not Available
Yawning22.12.03.0370.000166%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.002853%Not Available
Multiple sclerosis relapse17.16.01.003--Not Available
Fibromyalgia15.05.02.0020.005555%Not Available
Musculoskeletal disorder15.03.05.0250.001629%Not Available
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.008--Not Available
Joint range of motion decreased15.01.02.0060.000508%
Poor venous access24.03.02.017--Not Available
Dermatosis23.03.03.0170.000078%Not Available
Energy increased08.01.03.0170.000254%Not Available
Myofascial pain syndrome15.05.02.0030.000176%Not Available
Deafness unilateral04.02.01.0110.000130%Not Available
Hypoacusis04.02.01.0060.014201%
Paradoxical drug reaction08.06.01.0140.000078%Not Available
Peripheral swelling02.05.04.015; 08.01.03.0530.015280%Not Available
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.0060.000130%
Brain oedema17.07.02.003; 12.01.10.010--
Carotid artery occlusion24.04.06.008; 17.08.01.012--Not Available
Weight fluctuation14.03.02.0020.000436%Not Available
Emotional distress19.04.02.008--Not Available
Visual brightness17.17.02.009; 06.02.06.015--Not Available
Red blood cell sedimentation rate increased13.01.03.001--Not Available
Psychomotor skills impaired19.22.01.002; 17.02.10.0050.000207%Not Available
Onychomadesis23.02.05.0060.000114%
Lip blister23.03.01.016; 07.05.01.0070.000280%Not Available
Sudden cardiac death08.04.01.008; 02.03.04.0160.000078%Not Available
The 33th Page    First    Pre   33 34 35 36 37    Next   Last    Total 46 Pages